Comparison of different doses botulinum toxin type a efficacy in chronic anal fissure treatmentстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 11 мая 2022 г.
Аннотация:Objective: To compare the results of chronic anal fissure treatment with 10 IU and 40 IU botulinum toxin type A.Patients and methods: 56 patients were enrolled in case-controlstudy divided into 2 groups consistent by the main clinical criteria. 28 patients in the study group had fissure excision in combination with 10 IU botulinum toxin type A (Xeomin) injection intointernal anal sphincter, while 28 patients in control group received 40 IU product injections.Results: No statistically significant results in the pain assessmentduring the day and after bowel movement were obtained (p=0.41and p=0.93, respectively). The groups were comparable by thefrequency of complications such as transient anal incontinence,perianal skin hematoma, acute urinary retention (p>0.05). Complications such as thrombosis of external hemorrhoids andchronic non-healing wounds were most common in the studygroup (p=0.43 and p=0.0005, respectively). The product dose increase to 40 IU has a more significant effect on the functionaltreatment results (p=0.0053 and p=0.0002, respectively) and increases the odds for postoperative wound epithelialization 15-fold(p=0.01). Conclusion: 40 IU Botulinum toxin type A shows improvement in the treatment of chronic anal fissure without any increased risk of postoperative complications